BMS-986020
- Generic Name
- BMS-986020
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26N2O5
- CAS Number
- 1257213-50-5
- Unique Ingredient Identifier
- 38CTP01B4L
- Background
BMS-986020 is under investigation in clinical trial NCT02017730 (To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers).
Lilly's Olumiant Shows Promise in Preserving Beta Cell Function in Type 1 Diabetes
• Phase 2 BANDIT trial demonstrates Eli Lilly's Olumiant (baricitinib) can slow progression of type 1 diabetes by preserving insulin-producing beta cell function over 48 weeks of treatment.
• Patients receiving Olumiant required significantly less insulin therapy and experienced decreased blood glucose fluctuations compared to placebo, potentially reducing treatment burden.
• Researchers identify TYK2 inhibition as another promising approach for type 1 diabetes treatment, with an FDA-approved psoriasis drug potentially offering a dual mechanism to protect beta cells and reduce inflammation.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath